Is tumour lysis syndrome a recognised risk when lenalidomide is used for mantle cell lymphoma or follicular lymphoma?

Yes, tumour lysis syndrome is a recognised risk with lenalidomide for mantle cell lymphoma or follicular lymphoma; all patients should receive prophylaxis, oral hydration during the first cycle’s first week or longer if clinically indicated, and weekly chemistry monitoring during that cycle and as clinically indicated.